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Clinical use of doxorubicin (DOX) is limited by its cardiotoxic side eﬀects. Recent studies established that metformin (MET), an
oral antidiabetic drug, possesses an antioxidant activity. However, whether it can protect against DOX-induced energy starvation
and mitochondrial damage has not been reported. Our results, in a rat model of DOX-induced cardiotoxicity, show that DOX
treatment signiﬁcantly increased serum levels of LDH and CK-MB, indicators of cardiac injury, and induced expression of
hypertrophic gene markers. DOX also caused marked decreases in the cardiac levels of glutathione, CoA-SH and ATP, and
mRNA expression of catalase and NQO-1. These biochemical changes were associated with myocardial histopathological and
ultrastructural deteriorations, as observed by light and electron microscopy, respectively. Cotreatment with MET (500mg/kg)
eliminated all DOX-induced biochemical, histopathological, and ultrastructural changes. These ﬁndings demonstrate that MET
successfully prevents DOX-induced cardiotoxicity in vivo by inhibiting DOX-induced oxidative stress, energy starvation, and
depletion of intramitochondrial CoA-SH.
1.Introduction
The clinical use of doxorubicin (DOX), an anthracycline
antibiotic, can have both favorable and unfavorable conse-
quences. On the one hand, DOX is one of the most potent
antitumor agents available; on the other hand, its use is
limited by development of dose-dependent cardiomyopathy
involving cardiomyocyte apoptosis and myocardial ﬁbrosis
that may lead to congestive heart failure usually refractory
to common medications [1]. Although there is a linear
relationship between the cumulative dose received and the
incidence of cardiotoxicity, cardiotoxicity may develop in
somepatientsatdosesbelowthegenerallyacceptedthreshold
level [2]. Considerable research has focused on elucidating
the mechanisms of DOX-induced cardiomyopathy, aiming
at ﬁnding ways to prevent the development of cardiotox-
icity. Several mechanisms have been reported, including
generation of free radicals and lipid peroxidation of cardiac
membranes[3],myocytedamageinducedbycardiaccalcium
overload [4], formation of DOX-iron complex [5], impaired
myocardial adrenergic regulation, cellular toxicity of anthra-
cycline metabolites [6], and inhibition of beta-oxidation
of long chain fatty acids with the consequent depletion of
cardiac ATP [7].
Because of the undisputed key role that DOX plays in the
treatment of many neoplastic diseases, one of the research
aims being pursued most intensively is the possibility of
eliminating its cardiotoxicity or reducing it to an acceptable
level. If the cardiac complications resulting from DOX could
be prevented or at least reduced, higher doses could poten-
tially be utilized, thereby increasing cancer cure rates. In this
regard,variousdrugs,includingL-carnitine[8],dexrazoxane2 Oxidative Medicine and Cellular Longevity
[9], vitamin E [10], melatonin [11], and resveratrol [12],
have been shown to protect against DOX-induced cardiotox-
icity. Noticeably, a common theme among these therapeutic
approaches is that free radical generation by DOX is being
targeted. This highlights the critical role of oxidative stress
in DOX-induced cardiac toxicity. This is supported by the
ﬁndings demonstrating that DOX induces cardiomyocyte
apoptosis by reactive oxygen species-dependent mechanism
[6, 13]. Interestingly, this pathway has been found to be
distinct from apoptosis induced by DOX in tumor cells [14].
The prevalence of glucose intolerance is increased in
patients with malignancy [15]. Marks and Bishop [16]h a v e
reported that patients with malignant disease had a signiﬁ-
cantly lower net rate of disappearance of glucose, compared
with the control subjects. In addition, DOX itself, at ther-
apeutic doses, has been reported to be highly toxic to
endocrine function mainly on insulin secretion [17]. More-
over, glucocorticoids are often included with other agents in
cancer treatment to prevent side eﬀects [18, 19]. However,
administration of glucocorticoids is commonly associated
with impairment of insulin sensitivity, elevations in periph-
eral glucose levels, and the suppression of the hypothalamic-
pituitary-adrenal axis [20]. Insulin resistance is correlated
with an enhanced risk for cancer. In addition, the rate of
tumor recurrence, metastatic spread, and fatal outcome is
higher in cancer patients with hyperglycemia or type II dia-
betes, as compared with tumor patients without metabolic
disease [21]. Taken together, all these previously mentioned
ﬁndings emphasize the need for an adjuvant drug to be given
along with DOX to patients with malignancy, in order to
improve glucose tolerance and prevent DOX-induced cardi-
otoxicity.
Metformin (MET) is an oral biguanide antihyperglyce-
mic drug that is widely used for the management of type
2 diabetes mellitus. Therapeutic eﬀects of MET have been
attributed to a combination of improved peripheral uptake
and utilization of glucose, decreased hepatic glucose output,
decreased rate of intestinal absorption of carbohydrates, and
enhanced insulin sensitivity [22, 23]. Beyond its glucose-
lowering eﬀects, MET has been shown to exhibit antioxidant
properties in various tissues, an eﬀect that is independent
of its eﬀect on insulin sensitivity and acts to decrease lipid
peroxidation [24, 25]. Further, MET has been demonstrated
to exert cardioprotective eﬀects that could be due to its direct
beneﬁcial eﬀects on cellular and mitochondrial function
and therefore be independent of its insulin-sensitizing eﬀect
[26]. Noteworthy, MET has been recently shown to signif-
icantly improve left ventricular function and survival via
activation of AMP-activated protein kinase (AMPK) in an in
vivo murine model of heart failure [27].
Based on the aforementioned information, we hypoth-
esized that MET, by virtue of its antioxidant and cardio-
protective eﬀects, can protect against DOX-induced car-
diomyopathy. The overall objective of the present study
was to determine the extent to which MET can protect
against DOX-induced-energy starvation and mitochondrial
damage and to determine the possible mechanism of this
protection. Results from this study may shed the light on the
usefulnessofMET,asasafe,clinicallyapproveddrug,insuch
pathological situations.
2.MaterialsandMethods
2.1. Animals. Adult male Wistar albino rats, weighing 230–
250g, were obtained from the Animal Care Center, College
of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Animals were housed in metabolic cages under controlled
environmental conditions (25◦C and a 12h light/dark cycle).
Animals had free access to pulverized standard rat pellet diet.
The protocol of this study has been approved by the Research
EthicsCommitteeofCollegeofPharmacy,KingSaudUniver-
sity, Riyadh, Saudi Arabia.
2.2. Chemicals. DOX was a generous gift from the King
Khalid University Hospital drug store. MET, acetyl-CoA,
CoA-SH, adenosine triphosphate, and adenosine diphos-
phate were purchased from Sigma Chemical Company (St.
Louis, MO, USA). TRIzol reagent was purchased from Invit-
rogen Co. (Grand Island, NY, USA). The high-capacity
cDNA reverse transcription kits and SYBR Green PCR Mas-
ter Mix were purchased from Applied Biosystems (Foster
City, CA, USA). Metformin was dissolved in normal saline
and administered orally at low dose (100mg/kg) and high
dose (500mg/kg). All other chemicals were of the highest
commercially available analytical grade.
2.3. Experimental Design and Treatment Protocol. In this
study, the DOX treatment regimen used to develop the
cumulative cardiotoxicity was adopted from Beanlands et al.
[28] and Sayed-Ahmed et al. [29], while MET dosages (50
and 500mg/kg, p.o.) were selected based on studies by
AnuragandAnuradha[30]andWangetal.[31],respectively.
A total of 60 adult male Wistar albino rats were randomly
divided into 6 groups of 10 animals each. In the ﬁrst group,
animals were injected intraperitoneally (i.p.) with normal
saline (2.5mL/kg) and served as a normal control. Animals
inthesecondgroupwereinjected,everyotherday,withDOX
(3mg/kg, i.p.) over a period of 11 days to obtain cumulative
dose of 18mg/kg. Animals in the third and fourth groups
received MET (50, 500mg/kg, p.o., daily), respectively, over
a period of 11 days. Animals in the ﬁfth group were injected
every other day with DOX (3mg/kg, i.p.) as in group 2 and
daily treated with MET (50mg/kg, p.o.) over a period of 11
days. Animals in group 6 were injected every other day with
DOX (3mg/kg, i.p.) as in group 2 and daily treated with
MET (500mg/kg, p.o.) over a period of 11 days. Twenty-
four hours after receiving the last dose of DOX, animals were
anesthetized with light ether anesthesia, and blood samples
were obtained from the retro-orbital sinus of the eye. Serum
was separated for measurement of lactate dehydrogenase
(LDH) and creatine phosphokinase iso-enzyme MB (CK-
MB). Immediately after collection of blood samples, animals
were sacriﬁced and hearts were quickly excised, washed with
saline, blotted with a ﬁlter paper, and homogenized as indi-
cated in the procedures of measurement of each parameter,
using a Branson homogenizer (250, VWR Scientiﬁc, Dan-
bury, CT., USA).Oxidative Medicine and Cellular Longevity 3
2.4. Assessment of Serum Levels of Cardiac Enzymes. Serum
levels of LDH and CK-MB were determined according to the
methods of Buhl and Jackson [32]a n dW ua n dB o w e r s[ 33],
respectively.
2.5. Determination of CoA-SH and Acetyl-CoA in Isolated
Rat Heart Mitochondria. Free CoA-SH and acetyl-CoA were
determinedinisolatedratheartmitochondriausingHPLCas
described previously [34]. Brieﬂy, mitochondria were mixed
with ice-cold 6% perchloric acid and centrifuged at 300×g
for 5min at 0.5◦C. The resulting supernatant ﬂuid was
neutralized to pH 6-7 and then injected into the HPLC appa-
ratus. Chromatographic separation was performed using
ODS-Hypersil, 150 × 4.6mm i.d., 5μm column (Supelco
SA, Gland, Switzerland). The UV detector was adjusted at
254nm and set at 0.005. A mobile phase of 220mM potas-
sium phosphate, containing 0.05% dithioglycol (A) and 98%
methanol/2% chloroform (B), was used. The ﬂow rate was
0.6mL/min, and the gradient was as follows: at zero time,
94% A and 6% B; at 8min, 92% A and 8% B; at 14min, 87%
A and 13% B; at 25min, 80% A and 20% B; at 40min, 55%
A and 45% B; at 60min, 94% A and 6% B.
2.6. Measurement of Adenosine Triphosphate in Cardiac
Tissue. Adenosine triphosphate (ATP) was determined in
hearttissuesusinghigh-performanceliquidchromatography
(HPLC) as described by Botker et al. [35]. In brief, heart
tissue was homogenized in ice-cold 6% perchloric acid and
centrifuged at 3000rpm for 15min at 0.5◦C, and the super-
natant ﬂuid was injected into the HPLC system (Kontron
Instrument, Milano, Italy) after neutralization to pH 6-7.
Chromatographic separation was performed at a ﬂow rate
of 1.2mL/min, using ODS-Hypersil, 150 × 4.6mm I.D.,
5μm column (Supelco SA, Gland, Switzerland) and 75mM
ammonium dihydrogen phosphate as the mobile phase. The
peak elution was followed at 254nm.
2.7. Determination of Reduced Glutathione in Cardiac Tissues.
Cardiac tissue levels of the acid-soluble thiols, mainly re-
duced glutathione (GSH), were assayed spectrophotometri-
cally at 412nm, according to the method of Ellman [36]. The
contents of GSH were expressed as μmol/g wet tissue.
2.8. Histopathology and Electron Microscopy. The heart tis-
sues from all studied groups of rats were analyzed at both
histopathological and electron microscopic levels. Three-
micron thick sections were performed on the formalin-ﬁxed,
paraﬃn-embedded tissue of the heart, and the sections were
stained with routine hematoxylin and eosin stains (H&E).
The sections were studied under the optic routine micro-
scope by the histopathologists involved in the study.
The heart tissues submitted for electron microscopy
examination were ﬁxed in 3% glutaraldehyde. The tissues
were embedded in osmium tetroxide, and the semithin sec-
tions were stained with toluidine blue. The adequacy of the
sample in each case was checked on the semithin sections.
The thin sections were stained with uranyl acetate and lead
citrate, then all the sections were examined and photo-
graphed by the same histopathologists.
2.9. RNA Preparation and Quantitative Real-Time PCR.
To determine the eﬀect of DOX and/or MET on mRNA
expression levels of cardiac hypertrophic gene mark-
ers (α-MHC and β-MHC) and oxidative stress-mediated
genes (glutathione S-transferase-α (GSTα), catalase (CAT),
NAD(P)H:quinone oxidoreductase 1 (NQO1) and heme
oxygenase 1 (HO-1)), we conducted quantitative real-time
polymerase chain reaction (qRT-PCR), as follows.
2.9.1. RNA Extraction and cDNA Synthesis. Total RNA from
the heart tissue homogenate was isolated using TRIzol
reagent (Invitrogen) according to the manufacturer’s in-
structions and quantiﬁed by measuring the absorbance at
260nm; the RNA quality was determined by measuring
the 260/280 ratio. Thereafter, ﬁrst strand cDNA synthesis
was performed using the high-capacity cDNA reverse tran-
scription kit (Applied Biosystems), according to the man-
ufacturer’s instructions. Brieﬂy, 1.5μgo ft o t a lR N Af r o m
each sample was added to a mix of 2.0μL of 10x reverse
transcriptase buﬀer, 0.8μL of 25x dNTP mix (100mM),
2.0μL of 10x reverse transcriptase random primers, 1.0μLo f
MultiScribe reverse transcriptase, and 3.2μLo fn u c l e a s e - f r e e
water. The ﬁnal reaction mix was kept at 25◦C for 10min,
heated to 37◦C for 120min, heated for 85◦Cf o r5 s ,a n d
ﬁnally cooled to 4◦C.
2.9.2. Quantiﬁcation of mRNA Expression by qRT-PCR.
Quantitative analysis of mRNA expression of target genes
was performed by RT-PCR through subjecting the resulting
cDNA to PCR ampliﬁcation using 96-well optical reaction
plates in the ABI Prism 7500 System (Applied Biosystems).
The 25μL reaction mix contained 0.1μLo f1 0μMf o r w a r d
primer and 0.1μLo f1 0μM reverse primer (40nM ﬁnal con-
centration of each primer), 12.5μL of SYBR Green Universal
Master Mix, 11.05μL of nuclease-free water, and 1.25μL
of cDNA sample. The primers used in the current study
are listed in Table 1. Assay controls were incorporated onto
the same plate, namely, no-template controls to test for the
contamination of any assay reagents. The real-time PCR data
were analyzed using the relative gene expression (i.e., ΔΔCT)
method,asdescribedinAppliedBiosystemsUserBulletinno.
2. Brieﬂy, the data are presented as the fold change in gene
expression normalized to the endogenous reference gene β-
actin and relative to a calibrator.
2.10. Statistical Analysis. The data are expressed as mean ±
standard error of the mean (SEM). The signiﬁcance of diﬀer-
ences among groups was evaluated with one-way analysis of
variance (ANOVA) followed by the Tukey-Kramer multiple
comparison test. P values of 0.05 or less were considered
signiﬁcant.
3. Results
3.1. MET Protects against DOX-Induced Cardiac Myocyte
Injury. Table 2 shows the eﬀects of DOX, MET, and DOX
plus MET on the serum level of cardiotoxicity enzymatic
indices, CK-MB and LDH, in rats. Administration of DOX
(3mg/kg) every other day over a period of 11 days resulted4 Oxidative Medicine and Cellular Longevity
Table 1: Primers sequences used for real-time PCR reactions.
Primer set Sense primer 5  → 3  Antisense primer 5  → 3 
α-MHC GGACCACCCATCCTCACTTT AGCCTCTCATCTCGCATCTC
β-MHC ACCGCTGAGACAGAGAATGG GGGTTGGCTTGGATGATTT
GSTα GCTTTACTGTGCAAGGGAGACA GGAAGGAGGATTCAAGTCAGGA
CAT CCCGAGTCCAGGCTCTTCT CGGCCTGTACGTAGGTGTGA
NQO1 CGCAGACCTTGTGATATTCCAG TGTTGCGCTCAATCTCCTCCT
HO-1 ATGGCCTCCCTGTACCACATC CGTTTCTTCCATCCTTCCAGG
β-Actin CTGGCACCCAGGACAATG GCCGATCCACACGGAGTA
Table 2:TheprotectiveeﬀectofMETagainstDOX-inducedcardiac
myocyte injury.
Treatment group CK-MB (U/L) LDH (U/L)
Control 331 ±16 342 ±35
DOX 1125 ±94
∗ 1299 ±122
∗
MET, 50mg/kg 342 ± 24# 375 ±25#
MET, 500mg/kg 349 ± 36# 354 ±32#
DOX + MET, 50mg 903 ±69
∗ 1030 ± 67
∗
DOX + MET, 500mg 439 ± 47# 417 ±36#
All data represent mean values ± SEM (n = 10).
∗indicates signiﬁcant change from control, at P<0.05.
#indicates signiﬁcant change from DOX, at P<0.05.
Table 3: MET rescues the myocardium from DOX-induced
depletion of intramitochondrial CoA-SH.
Treatment groups CoA-SH (nmol/mg
protein)
Acetyl-CoA
(nmol/mg protein)
Control 3.26 ±0.16 13.41 ±0.62
DOX 1.89 ±0.24
∗ 22.31 ±0.89
∗
MET, 50mg/kg 2.91 ±0.29# 12.19 ±0.59#
MET, 500mg/kg 4.22 ±0.20
∗# 8.01 ±0.40
∗#
DOX + MET, 50mg/kg 2.77 ±0.16 19.28 ±0.93
∗
DOX + MET, 500mg/kg 3.06 ±0.18# 15.44 ±0.78#
All data represent mean values ± SEM (n = 10).
∗indicates signiﬁcant change from control, at P<0.05.
#indicates signiﬁcant change from DOX, at P<0.05.
in a signiﬁcant 240% and 280% increases in serum LDH
and CK-MB, respectively, as compared to the control group.
Treatment with MET at dose level either 50mg/kg or
500mg/kg for 11 successive days showed nonsigniﬁcant
changesascomparedtothecontrolgroup.Interestingly,daily
administration of MET (500mg/kg) to DOX-treated rats
resulted in a complete reversal of DOX-induced increase in
serum CK-MB and LDH to the control values. However,
administration of the small dose of MET (50mg/kg) did not
prevent DOX-induced increase in cardiac enzymes.
3.2. MET Rescues the Myocardium from DOX-Induced Deple-
tion of Intramitochondrial CoA-SH. The eﬀects of DOX,
MET,andDOXplusMETonthelevelofCoA-SHandacetyl-
CoA in isolated rat heart mitochondria are shown in Table 3.
Treatment with DOX resulted in a signiﬁcant 42% decrease
inCoA-SHlevelandasigniﬁcant66%increaseinacetyl-CoA
inisolatedratheartmitochondriaascomparedtothecontrol
group. Treatment with MET (500mg/kg) alone resulted in
a signiﬁcant 30% and 123% increase in CoA-SH level and a
signiﬁcant40%and45%decreaseinacetyl-CoAascompared
to the control and DOX groups, respectively. Interestingly,
daily administration of the high dose of MET (500mg/kg) to
DOX-treated rats resulted in a complete prevention of DOX-
induced decrease in CoA-SH and increase in acetyl-CoA to
the control values.
3.3. MET Protects the Myocardium against DOX-Induced
Energy Starvation. Figure 1 shows the eﬀects of DOX, MET,
and DOX plus MET on ATP level in cardiac tissues. Treat-
ment with a total cumulative dose of DOX (18mg/kg) re-
sulted in a signiﬁcant decrease (31.5%) in ATP level in
cardiac tissues as compared to the control group. However,
treatment with MET (500mg/kg) for 11 successive days
caused a signiﬁcant increase (54%) in ATP as compared to
thecontrolgroup.Interestingly,dailyadministrationofMET
(500mg/kg) to DOX-treated rats resulted in a complete
reversal of DOX-induced decrease in ATP to the control
values. However, administration of the small dose of MET
(50mg/kg) did not alter DOX-induced decrease in ATP level
in cardiac tissues.
3.4. MET Reverses the Eﬀect of DOX on Cardiac GSH Level.
Figure 2 shows the eﬀects of DOX, MET, and DOX plus
MET on GSH level in rat cardiac tissues. Treatment with
a total cumulative dose of DOX (18mg/kg) resulted in a
signiﬁcant 57% decrease in GSH level, as compared to the
control group. Treatment with MET at dose level either
50mg/kg or 500mg/kg for 11 successive days resulted in a
signiﬁcant and dose-dependent (70% and 102%) increase in
GSH level, respectively, as compared to the control group.
Daily administration of MET either 50mg/kg or 500mg/kg
to DOX-treated rats resulted in a complete reversal of DOX-
induced decrease in cardiac GSH level to the control values.
3.5. Histopathology and Electron Microscopy. The light
microscopic examination of the normal control rat hearts
showed normal architecture and cytological features
(Figure 3(i)). However, examination of the heart tissues of
DOX-alone-treated rats revealed focal mild inﬂammation
of the myocardium (arrows in Figure 3(ii)) that was
associated with myocardial ﬁber injury, in addition to
vacuolar changes of the cytoplasm of some myocardial cellsOxidative Medicine and Cellular Longevity 5
(arrow in Figure 3(ii) B). The inﬂammatory inﬁltrate con-
sisted of lymphocytes, plasma cells, and histiocytes, with
prominent mononuclear chronic inﬂammatory appearance
that replaced the degenerated myocardial muscle ﬁbers
with apparent hypereosinophilia (Figure 3(ii) A and B).
Treatment with MET alone (50 or 500mg/kg) showed no
pathological changes in the tested heart tissues, while, in the
group that received MET (50mg/kg) and DOX, the heart
tissues showed few mild inﬂammatory foci with undetected
myocardial injury (Figure 3(iii) A and B). The heart tissues
of the rats that received MET (500mg/kg) and DOX revealed
almost normal morphological tissue appearance without
any detected inﬂammation or tissue injury (Figure 3(iv) A
and B).
The electron microscopic examination of normal con-
trol rat hearts revealed normal mitochondria (arrow in
Figure 4(i) A) with preserved internal architectures and
surrounding organized myoﬁbrils (arrow in Figure 4(i) B).
The heart tissues of DOX-treated rats exhibited a prominent
component of patchy myoﬁbrillar loss and disarray, in addi-
tiontoprominenthypercontractionbandswithprominentA
bandloss(Figure 4(ii)AandB).Moreover,themitochondria
showed remarkable abnormalities that included enlarge-
ment, contour irregularities, increased spacing between the
cristae and disruption of the internal architecture (arrow
in Figure 4(ii) B). The group of rats treated with 50mg/kg
or 500mg/kg of MET illustrated no signiﬁcant ultrastruc-
tural changes. Hearts of rats treated with MET (50mg/kg)
and DOX showed some focal but prominent pathological
ﬁndings. In this focus, there was an evidence of loss of
myoﬁbrils in addition to mitochondrial size and shape
variation and many dilated lysosomes (arrow in Figure 4(iii)
A). On the contrary, a signiﬁcant improvement was seen in
the ultrastructure of the hearts of rats treated with MET
500mg/kg and DOX (Figure 4(iv) A and B). The examined
sections showed a normal mitochondrial size and shape with
normal arrangement of cristae.
3.6. MET Reverses DOX-Mediated Changes in the Levels of
Cardiac Hypertrophic Genes. To investigate the eﬀectof MET
on the expression of cardiac hypertrophic gene markers,
α-MHC and β-MHC mRNA levels were determined in
both healthy and DOX-induced cardiotoxic rats using RT-
PCR. Figure 5 shows that both doses of MET did not
signiﬁcantly alter the mRNA expression of both α-MHC
and β-MHC. On the other hand, DOX-treated rats showed
a signiﬁcant decrease in the mRNA level of α-MHC by
approximately 40%, whereas β-MHC mRNA level was
induced dramatically 250%. Importantly, administration
of MET signiﬁcantly restored DOX-mediated changes in
hypertrophic genes, which was more pronounced at the
highest dose (500mg/kg).
3.7. MET Restores DOX-Mediated Changes in the Levels of
Oxidative Stress-Related Genes. To further explore the role
of oxidative stress in the cardioprotective eﬀect of MET, we
have investigated the eﬀect of MET on the expression of four
oxidative stress-mediated genes, GSTα,C A T ,N Q O 1 ,a n d
HO-1. Figure 6 showed that induction of cardiotoxicity by
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Figure 1: MET protects the myocardium against DOX-induced
energy starvation. Rats (n = 10/per treatment type) received
normal saline, DOX in a total cumulative dose of 18mg/kg, MET
(50 or 500mg/kg, p.o., daily), or DOX plus either dose of MET.
24h after receiving the last dose of DOX, ATP was determined
in heart tissues using HPLC. Data are presented as mean ± SEM
(n = 10). ∗ and # indicate signiﬁcant change from control and
DOX,respectively,atP<0.05usingANOVAfollowedbytheTukey-
Kramer as a post-ANOVA test.
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Figure 2: MET reverses the eﬀect of DOX on cardiac GSH level.
Rats(n = 10/treatmenttype)receivednormalsaline,DOXinatotal
cumulative dose of 18mg/kg, MET (50 or 500mg/kg, p.o., daily)
or DOX plus either dose of MET. 24h after receiving the last dose
of DOX, cardiac tissue level of GSH was determined in rat cardiac
tissues. Data are presented as mean ± SEM (n = 10). ∗ and #
indicate signiﬁcant change from control and DOX, respectively, at
P<0.05 using ANOVA followed by the Tukey-Kramer as a post-
ANOVA test.
DOX was associated with upregulated expression of GSTα
(A) and HO-1 (B) which was accompanied with a signiﬁcant
decrease in CAT (C) and NQO1 (D) mRNA expression levels
as compared to control rats. Although treatment of control
rats with MET did not alter the expression of most target
genes, treatment of DOX-treated rats with MET signiﬁcantly
restored the DOX-induced modulations of all tested genes in
a dose-dependent manner, in that MET induced NQO1 and
CAT whereas inhibited GSTα and HO-1 mRNA expression
in a dose-dependent manner.6 Oxidative Medicine and Cellular Longevity
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100x 400x
Figure 3: MET protects myocardium against DOX-induced histopathological deteriorations. Photos (i) A and B show normal cardiac
structure derived from normal control rat. Photos (ii) A and B are derived from heart section of a rat treated with a total cumulative
dose of 18mg/kg DOX and shows myocardial ﬁber injury as vacuolar changes of the cytoplasm and inﬂammatory inﬁltrate consisting of
lymphocytes, plasma cells and histiocytes (arrow). Photos (iii) A and B show heart sections derived from a rat treated with MET 50mg/kg
prior to a total cumulative dose of 18mg/kg DOX. It shows few inﬂammatory foci with considerable improvement in heart histology. Photos
(iv) A and B illustrate heart sections obtained from a rat pretreated with MET 500mg/kg before a total cumulative dose of 18mg/kg DOX,
revealing almost normal histology with a marked improvement in heart histology. Magniﬁcation, 400x in A; 100x in B.
4. Discussion
The most common hypothesis for the mechanism of DOX-
induced cardiac injury is the increase of oxidative stress. Free
radical generation by DOX, which is usually associated with
a depression of GSH in heart tissue, results in disruption of
cellular membrane integrity. This hypothesis is supported
by the several reports that have shown that antioxidants,
including vitamins E and A, resveratrol, and selenium, pro-
tect cardiomyocytes against the toxicity of DOX [37]. On theOxidative Medicine and Cellular Longevity 7
(i)
(ii)
(iii)
(iv)
Low power High power
AB
A B
A B
AB
Figure 4: MET protects myocardium against DOX-induced ultrastructural deteriorations. Photos (i) A and B show normal ultrastructure
of a normal control rat heart. Photos (ii) A and B are EM photo taken for a heart section from a rat treated with a total cumulative dose
of 18mg/kg DOX and show a prominent component of patchy myoﬁbrillar loss and disarray, hypercontraction bands with prominent A
band loss. They also show mitochondrial abnormalities, including enlargement and irregular contour. Photos (iii) A and B are photos of
ultrastructure of rat heart treated with MET 50mg/kg prior to a total cumulative dose of 18mg/kg DOX and show mild improvement
in the mitochondrial structure. Photos (iv) A and B are photos of ultrastructure of cardiac muscle derived from a rat treated with MET
500mg/kg prior to a total cumulative dose of 18mg/kg DOX, showing almost normal ultrastructure, size, and shape of the myocardial
ﬁbers. Magniﬁcation, low power in A; high power in B.
other hand, impairment of cardiac high-energy phosphate
metabolism has been recognized as an important feature
of both acute and chronic DOX cardiotoxic action. These
energetic deﬁcits have been associated with compromised
mitochondrial function [38]. In this context, oxidative dam-
age to cardiac mitochondria and to cardiomyocytes has
been widely implicated as a primary cause for doxorubicin-
inducedcardiactoxicity[39,40].Theenhancedgenerationof
ROS by DOX may directly damage mitochondria or alter the
synthesis of proteins associated with the mitochondrial elec-
tron transport chain, with the subsequent inhibition of oxi-
dative phosphorylation and decrease in cardiac high-energy
phosphate homeostasis [41, 42]. The accumulation of vari-
ous deﬁciencies in high-energy phosphate metabolism may
be a very critical step for the DOX-induced deterioration
of cardiac function and for the onset of chronic clinical
cardiotoxicity [43].
The model utilized in the present study has already been
established in previous publications that included biomark-
ers of cardiotoxicity as those reported by Beanlands et al.8 Oxidative Medicine and Cellular Longevity
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Figure 5: MET reverses DOX-mediated changes in the levels of cardiac hypertrophic genes. Rats (n = 10/treatment type) received normal
saline, DOX in a total cumulative dose of 18mg/kg, MET (50 or 500mg/kg, p.o., daily), or DOX plus either dose of MET. 24h after receiving
the last dose of DOX, total RNA was isolated from rat cardiac tissue using TRIzol methods and quantiﬁed spectrophotometrically at 260nm.
The mRNA levels of α-MHC (a) and β-MHC genes (b) were quantiﬁed using RT-PCR and normalized to β-actin housekeeping gene. Values
represent mean of fold change ± SEM (n = 10).
∗P < 0.05 compared with control rats. +P < 0.05 compared with DOX-treated rats.
1994 [28] and Sayed-Ahmed et al. 2010 [29]. In the latter
study, rats were injected every other day with doxorubicin
(3mg/kg,i.p.),toobtaintreatmentswithcumulativedosesof
6, 12, and 18mg/kg. The cumulative cardiotoxicity of DOX
was clearly featured in that study by the dose-dependent
increase in serum cardiac enzymes CK-MB and LDH. At
the highest cumulative dose, 18mg/kg, DOX resulted in a
signiﬁcant increase in CK-MB and LDH and decrease in ATP
as well as the expression of apoptotic genes, as compared
to the control group. That is why we decided to use that
samehighestcumulativedosetoproducethemodelofDOX-
induced cardiotoxicity on the cellular and molecular levels,
rather than functional ones, using the same animal species.
Since DOX causes disruption of cardiac myocyte cell
membranes, the release of intracellular proteins, such as
LDH and CK-MB, into serum has been used to assay for the
presence and extent of cardiac myocyte injury [6, 44]. The
levelsofthesetwoenzymesweremarkedlyincreased byDOX
administration in our study. Our results are in a good agree-
mentwithpreviousreports[45,46].Inaddition, histopatho-
logical investigation of cardiac tissues from DOX-treated
rats showed myocardial mononuclear chronic inﬂamma-
tion that replaced the degenerated muscle ﬁbers aﬀected.
Electron microscopic examination revealed the presence of
morphological evidences of mitochondrial injury, as well
as myoﬁbrillar loss and disruption. Moreover, treatment
with DOX increased β-MHC expression and decreased α-
MHC expression, as a result of cardiac toxicity. This is
consistent with earlier published data [47–50]. All these
biochemical and molecular changes and histopathological
deteriorations were completely prevented by MET therapy
(500mg/kg, every day). These results suggest that MET
therapy during DOX treatment for cancer oﬀers substantial
protection of the heart against DOX-induced injury. The
initial damage caused by DOX is believed to be oxidative
in nature. This drug can undergo one electron reduction to
the corresponding semiquinone, leading to the generation of
superoxide radical [51]. DOX interacts with iron, generating
a DOX-ferric iron free radical complex, and the resulting
complex catalyzes the conversion of hydrogen peroxide to
thehighlyreactivehydroxylradical.Hydrogenperoxide,lipid
peroxides, superoxide radical, and hydroxyl radical can dam-
age membranes, macromolecules, and mitochondria and
may cause direct myocardial injury [2, 51]. Notably, mam-
malian hearts are vulnerable to DOX cardiotoxicity due to
limited antioxidant mechanisms that could protect them
from oxidative injury [2, 52].
In the present study, total content of GSH, the most
important endogenous antioxidant, was assessed as a marker
for oxidative stress, since reduced GSH normally represents
more than 90% of cellular GSH content [53]. The method
used in this study utilized Ellman’s reagent which determines
total SH-containing compounds, which are mainly repre-
sented as reduced GSH [54, 55]. Also, the gene expression
of the oxidative stress molecular markers, NQO-1, catalase,
HO-1, and GST-α, has been investigated to elaborate more
on the oxidative stress pathway. Moreover, it has been re-
ported that DOX itself causes the disappearance of glu-
tathioneperoxidaseandsigniﬁcantlylowersthelevelsofGSH
in heart tissue. This diminishes the capability of the heart to
dispose of hydrogen peroxide, making the heart more sus-
ceptible to redox injury [51, 52, 56, 57]. Cardiac tissue level
of GSH was demonstrated in our study to be signiﬁcantly
decreased by DOX treatment, which comes in agreement
with the previous report by Aleisa et al. [58]. Remarkably,
this decrease was completely prevented by the two doses (50Oxidative Medicine and Cellular Longevity 9
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Figure 6: MET restores DOX-mediated changes in the levels of oxidative stress-related genes. Rats (n = 10/treatment type) received normal
saline, DOX in a total cumulative dose of 18mg/kg, MET (50 or 500mg/kg, p.o., daily), or DOX plus either dose of MET. 24h after receiving
the last dose of DOX, total RNA was isolated from rat cardiac tissue using TRIzol methods and quantiﬁed spectrophotometrically at 260nm.
The mRNA levels of GSTα (a), HO-1 (b), CAT (c), and NQO1 (d) were quantiﬁed using RT-PCR and normalized to β-actin housekeeping
gene. Values represent mean of fold change ± SEM (n = 10).
∗P < 0.05 compared with control rats. +P < 0.05 compared with DOX-treated
rats.
and 500mg/kg/d) of MET, indicating its strong antioxidant
activity and its potential cardioprotective eﬃcacy against
DOX cardiotoxicity.
DOX also exerted dramatic eﬀects on the expression of
molecular oxidative stress markers. It induced the expression
of GSTα and HO-1 genes and decreased CAT and NQO1
mRNA expression as compared to control rats. DOX treat-
ment is known to enhance the production of the highly reac-
tive lipid peroxidation product 4-hydroxy-2-nonenal (HNE)
in cardiac tissue [59]. DOX-induced HNE has been shown
to be partially detoxiﬁed by conjugation with GSH by GST
to form the glutathione conjugate of HNE (GS-HNE) [60].
Induction of GSTα gene expression by DOX in the present
work reveals that cardiac tissues were defending themselves
against DOX toxicity by augmenting the expression of GSTα
which, in turn, consumed GSH to detoxify DOX. This is
evidenced by the signiﬁcant decrease of cardiac tissue level of
GSH by DOX (Figure 2). By virtue of its antioxidant activity,
MET released the pressure on cardiac tissue to augment
GSTα expression, thereby saving the cardiac levels of GSH
(Figure 2).
Moreover, the results showed that CAT, an enzyme
responsible for the removal of H2O2, gene expression is
decreased by DOX treatment, supporting the idea that DOX
induces a state of oxidative stress in the heart tissues. NQO1
is cytosolic enzyme that plays an essential role in the detoxi-
ﬁcation of quinones through two-electron reduction process
[61, 62]. In addition, NQO1 helps to maintain endogenous
antioxidants, in their active form [63]. It seems that the
decreaseinNQO1expressionbyDOXtreatmentinourstudy
is attributed to a direct inhibitory eﬀect. This may lead to
insuﬃcient NQO1 activity that could have buﬀered DOX-
oxidizing properties. Therefore,the heart washighly exposed
to oxidizing species induced by DOX. In the same sense,
DOX induced HO-1 gene expression which is the rate-
limiting enzyme of heme degradation, and it is a stress-
responsiveproteinthatrespondstomanykindsofchemically
or physiologically produced oxidative stress, including GSH10 Oxidative Medicine and Cellular Longevity
depletion, in various cells and tissues [64, 65]. Hence, the
induction of HO-1 gene expression by DOX could be
understood as a response of cardiac cells to DOX-induced
GSH depletion. MET, alone or along with DOX, decreased
HO-1 expression. This could be because MET itself possesses
a signiﬁcant antioxidant activity as shown above. The signif-
icant increase in the GSH level and CAT and NQO-1 mRNA
expression in heart tissue of animals after treatment with
MET supports the above hypothesis that MET ameliorates
DOX-induced oxidative stress. These results have extended
earlier ﬁnding by others that MET substantially increased
GSH level in normal rats [24] and protected against the
DOX-induced decrease of GSH in mice [58]. Interestingly,
Faure et al. [24] showed that this eﬀect was independent
of MET eﬀect on insulin activity. More recently, Asensio-
Lopezetal.[66]illustratedthatMETexertsaprotectiveeﬀect
against DOX-induced cardiotoxicity through the involve-
ment of the cardiac system of adiponectin and restoring the
activity of antioxidant enzymes in isolated cardiomyocytes in
vitro.
The most important role of mitochondria in the my-
ocardium is to supply cardiac cells with ATP, a crucial
source of energy for contraction and for the maintenance
of ion homeostasis, protein synthesis, and other important
cellular functions [67]. In that regard, DOX was shown to
inhibit long-chain fatty acid oxidation in the heart [68].
Underphysiologicalconditions,long-chainfattyacidsarethe
favored substrates for energy production in the heart [69].
Consequently, inhibition of long-chain fatty acid oxidation
results in a deﬁciency in ATP supply and accumulation
of toxic intermediates including long-chain fatty acyl-CoA
thioesters and long-chain acyl-carnitine derivatives in car-
diactissues,withsubsequentcardiomyopathy andcongestive
heart failure [70–72]. In the present study, level of ATP
in cardiac tissue was markedly reduced by DOX treatment.
In addition, DOX signiﬁcantly decreased level of CoA-SH,
an indispensable activator in most of the energy-providing
systems (TCA cycle, fatty acid oxidation) [73], and increased
that of acetyl-CoA, the main product of β-oxidation of fatty
acids. Acetyl-CoA is a strong inhibitor of 3-ketoacyl-CoA
thiolase, the enzyme catalyzing the last step in β-oxidation
of fatty acids, especially at low concentrations of CoA-SH
[74]. Therefore, in the present study, raising the acetyl-
CoA/CoA-SH ratio in isolated rat heart mitochondria by
DOX could inhibit fatty acid oxidation, with subsequent
deleterious eﬀects on cardiac energy supply. Therapy with
MET prevented the decrease of ATP and the increase of
acetyl-CoA/CoA-SH ratio induced by DOX. These data indi-
cate that MET protects myocardium against DOX-induced
energy starvation and depletion of intramitochondrial CoA-
SH. In that context, Gundewar et al. [27] have recently
reported that MET signiﬁcantly improves left ventricular
function and survival via activation of AMPK in a murine
model of heart failure. Activated AMPK phosphorylates a
variety of intracellular proteins to increase ATP generation
and decrease ATP utilization for processes not immediately
critical for survival [75].
Collectively, the data presented in this study suggest that
liberation of free radicals induced by DOX treatment causes
oxidative injury to heart tissues and organelles including
mitochondria. Since heart is almost entirely dependent on
ATP generatedby mitochondria for its functionand contrac-
tility [76], mitochondrial injury, with its subsequent depres-
sionofmyocardialATP,contributestotheprogressionofcar-
diac toxicity [77]. The oxidative injury to the heart is accen-
tuated by the reduction of the cardiac antioxidant defense,
represented by the great reduction of GSH content and CAT
and NQO-1 gene expression induced by DOX. Therefore,
our data suggest that the protective eﬀect of MET against
DOX-induced cardiac toxicity could originate from its
antioxidant activity.
5. Conclusion
Results from the present investigation reveal that DOX
induces its cardiotoxicity by decreasing cardiac level of CoA-
SH and increasing that of acetyl-CoA, with the consequent
inhibition of fatty acid oxidation and ATP generation. This is
aggravated by the increased susceptibility of the heart to oxi-
dant injury due to DOX-induced reduction of cardiac GSH
level, as well as the decrease in CAT and NQO-1 gene ex-
pression. Our ﬁndings demonstrate that MET prevents all
of these biochemical and molecular changes and other
histopathological and ultrastructural deteriorations in the
cardiac tissues, warranting its coadministration with DOX to
ameliorate its cardiotoxicity.
Conﬂict of Interests
The authors have no personal or ﬁnancial conﬂict of interest
and have not entered into any agreement that could interfere
with their access to the data on the research or upon their
ability to analyze the data independently, to prepare papers,
and to publish them.
Acknowledgment
This work was supported by a grant from the King Abdulaziz
City for Science and Technology (KACST; Grant no. ARP-
29-265). The technical assistance of Mr. Jamal Hardelo from
the Department of Pharmacology, College of Medicine, King
Saud University, is greatly appreciated.
References
[1] G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni,
“Anthracyclines: molecular advances and pharmacologie de-
velopmentsinantitumoractivityandcardiotoxicity,”Pharma-
cological Reviews, vol. 56, no. 2, pp. 185–229, 2004.
[2] M. S. Horenstein, R. S. Vander Heide, and T. J. L’Ecuyer,
“Molecular basis of anthracycline-induced cardiotoxicity and
itsprevention,”MolecularGeneticsandMetabolism,vol.71,no.
1-2, pp. 436–444, 2000.
[3] S. Rajagopalan, P. M. Politi, B. K. Sinha, and C. E. Myers,
“Adriamycin-induced free radical formation in the perfused
ratheart:implicationsforcardiotoxicity,”CancerResearch,vol.
48, no. 17, pp. 4766–4769, 1988.
[4] F. Rossi, W. Filippelli, S. Russo, A. Filippelli, and L. Berrino,
“Cardiotoxicity of doxorubicin: eﬀects of drugs inhibiting.Oxidative Medicine and Cellular Longevity 11
The release of vasoactive substances,” Pharmacology and Toxi-
cology, vol. 75, no. 2, pp. 99–107, 1994.
[5] T. Simunek, M.Sterba, O. Popelova, M.Adamcova, R.Hrdina,
and V. Gersl, “Anthracycline-induced cardiotoxicity: overview
of studies examining the roles of oxidative stress and free
cellular iron,” Pharmacological Reports, vol. 61, no. 1, pp. 154–
171, 2009.
[6] R. D. Olson and P. S. Mushlin, “Doxorubicin cardiotoxicity:
analysis of prevailing hypotheses,” The FASEB Journal, vol. 4,
no. 13, pp. 3076–3086, 1990.
[ 7 ] M .M .S a y e d - A h m e d ,S .A .S h o u m a n ,B .M .R e z k ,M .H .K h a l -
ifa, A. M. Osman, and M. M. El-Merzabani, “Propionyl-L-
carnitine as potential protective agent against adriamycin-
induced impairment of fatty acid beta-oxidation in isolated
heart mitochondria,” Pharmacological Research, vol. 41, no. 2,
pp. 143–150, 2000.
[8] V. De Leonardis, B. Neri, S. Bacalli, and P. Cinelli, “Reduction
of cardiac toxicity of anthracyclines by L-carnitine: prelimi-
naryoverviewofclinicaldata,”InternationalJournalofClinical
Pharmacology Research, vol. 5, no. 2, pp. 137–142, 1985.
[ 9 ] C .F .S e i f e r t ,M .E .N e s s e r ,a n dD .F .T h o m p s o n ,“ D e x r a z o x a n e
in the prevention of doxorubicin-induced cardiotoxicity,” An-
nals of Pharmacotherapy, vol. 28, no. 9, pp. 1063–1072, 1994.
[10] A. Puri, S. K. Maulik, R. Ray, and V. Bhatnagar, “Electrocar-
diographic and biochemical evidence for the cardioprotective
eﬀect of vitamin E in doxorubicin-induced acute cardiotoxic-
ity in rats,” European Journal of Pediatric Surgery, vol. 15, no.
6, pp. 387–391, 2005.
[11] I. Morishima, H. Matsui, H. Mukawa et al., “Melatonin, a
pineal hormone with antioxidant property, protects against
adriamycin cardiomyopathy in rats,” Life Sciences, vol. 63, no.
7, pp. 511–521, 1998.
[12] E. Tatlidede, O. Sehirli, A. Velioglu-Ogunc et al., “Resveratrol
treatmentprotectsagainstdoxorubicin-inducedcardiotoxicity
byalleviatingoxidativedamage,”FreeRadicalResearch,vol.43,
no. 3, pp. 195–205, 2009.
[13] E.Delpy,S.N.Hatem,N.Andrieuetal.,“Doxorubicininduces
slow ceramide accumulation and late apoptosis in cultured
adult rat ventricular myocytes,” Cardiovascular Research, vol.
43, no. 2, pp. 398–407, 1999.
[14] S. Wang, E. A. Konorev, S. Kotamraju, J. Joseph, S. Kalivendi,
and B. Kalyanaraman, “Doxorubicin induces apoptosis in
normal and tumor cells via distinctly diﬀerent mechanisms:
intermediacy of H2O2- and p53-dependent pathways,” Journal
of Biological Chemistry, vol. 279, no. 24, pp. 25535–25543,
2004.
[15] A. S. Glicksman and R. W. Rawson, “Diabetes and altered car-
bohydrate metabolism in patients with cancer,” Cancer, vol. 9,
no. 6, pp. 1127–1134, 1956.
[16] P. A. Marks and J. S. Bishop, “The glucose metabolism of pa-
tientswithmalignantdiseaseandofnormalsubjectsasstudied
bymeansofanintravenousglucosetolerancetest,”TheJournal
of Clinical Investigation, vol. 36, no. 2, pp. 254–264, 1957.
[17] M. Deleers and E. Goormaghtigh, “Adriamycin eﬀects on
insulin secretion, Ca2+ movements and glucose oxidation in
pancreatic islet cells,” Pharmacological Research Communica-
tions, vol. 17, no. 3, pp. 227–232, 1985.
[18] J. P. Ioannidis, P. J. Hesketh, and J. Lau, “Contribution of dex-
amethasone to control of chemotherapy-induced nausea and
vomiting: a meta-analysis of randomized evidence,” Journal of
Clinical Oncology, vol. 18, no. 19, pp. 3409–3422, 2000.
[19] R. E. Coleman, “Glucocorticoids in cancer therapy,” Biother-
apy, vol. 4, no. 1, pp. 37–44, 1992.
[20] A. Munck, “Glucocorticoid inhibition of glucose uptake by
peripheral tissues: old and new evidence, molecular mecha-
nisms, and physiological signiﬁcance.,” Perspectives in Biology
and Medicine, vol. 14, no. 2, pp. 265–269, 1971.
[21] Z. Suba and M. Ujp´ al, “Correlations of insulin resistance and
neoplasms,” Magyar onkologia., vol. 50, no. 2, pp. 127–135,
2006.
[ 2 2 ]K .C u s i ,A .C o n s o l i ,a n dR .A .D e f r o n z o ,“ M e t a b o l i ce ﬀects of
metformin on glucose and lactate metabolism in noninsulin-
dependent diabetes mellitus,” Journalof ClinicalEndocrinology
and Metabolism, vol. 81, no. 11, pp. 4059–4067, 1996.
[23] A. Klip and L. A. Leiter, “Cellular mechanism of action of
metformin,” Diabetes Care, vol. 13, no. 6, pp. 696–704, 1990.
[24] P. Faure, E. Rossini, N. Wiernsperger, M. J. Richard, A. Favier,
and S. Halimi, “An insulin sensitizer improves the free radical
defense system potential and insulin sensitivity in high fruc-
tose-fed rats,” Diabetes, vol. 48, no. 2, pp. 353–357, 1999.
[25] G. Kanigur-Sultuybek, M. Guven, I. Onaran, V. Tezcan, A.
Cenani, and H. Hatemi, “The eﬀect of metformin on insulin
receptors and lipid peroxidation in alloxan and streptozotocin
induced diabetes,” Journal of Basic and Clinical Physiology and
Pharmacology, vol. 6, no. 3-4, pp. 271–280, 1995.
[26] G. S. Bhamra, D. J. Hausenloy, S. M. Davidson et al., “Met-
formin protects the ischemic heart by the Akt-mediated inhi-
bition of mitochondrial permeability transition pore open-
ing,” Basic Research in Cardiology, vol. 103, no. 3, pp. 274–284,
2008.
[27] S. Gundewar, J. W. Calvert, S. Jha et al., “Activation of
AMP-activated protein kinase by metformin improves left
ventricular function and survival in heart failure,” Circulation
Research, vol. 104, no. 3, pp. 403–411, 2009.
[28] R. S. B. Beanlands, N. A. Shaikh, W. H. Wen et al., “Alterations
in fatty acid metabolism in adriamycin cardiomyopathy,”
Journal of Molecular and Cellular Cardiology, vol. 26, no. 1, pp.
109–119, 1994.
[29] M. M. Sayed-Ahmed, O. A. Al-Shabanah, M. M. Hafez, A. M.
Aleisa, and S. S. Al-Rejaie, “Inhibition of gene expression of
heart fatty acid binding protein and organic cation/carnitine
transporter in doxorubicin cardiomyopathic rat model,” Euro-
pean Journal of Pharmacology, vol. 640, no. 1–3, pp. 143–149,
2010.
[30] P. Anurag and C. V. Anuradha, “Metformin improves lipid
metabolism and attenuates lipid peroxidation in high fruc-
tose-fed rats,” Diabetes, Obesity and Metabolism,v o l .4 ,n o .1 ,
pp. 36–42, 2002.
[31] X. Wang, X. Jia, T. Chang, K. Desai, and L. Wu, “Attenuation
of hypertension development by scavenging methylglyoxal in
fructose-treated rats,” Journal of Hypertension,v o l .2 6 ,n o .4 ,
pp. 765–772, 2008.
[32] S. N. Buhl and K. Y. Jackson, “Optimal conditions and com-
parison of lactate dehydrogenase catalysis of the lactate to
pyruvate and pyruvate to lactate reactions in human serum
at 25, 30, and 37◦C.,” Clinical Chemistry, vol. 24, no. 5, pp.
828–831, 1978.
[ 3 3 ]A .H .W ua n dG .N .B o w e r sJ r . ,“ E v a l u a t i o na n dc o m p a r i s o n
of immunoinhibition and immunoprecipitation methods for
diﬀerentiating MB from BB and macro forms of creatine
kinase isoenzymes in patients and healthy individuals,” Clin-
ical Chemistry, vol. 28, no. 10, pp. 2017–2021, 1982.
[34] A. Longo, G. Bruno, S. Curti, A. Mancinelli, and G. Miotto,
“Determination of L-carnitine, acetyl-L-carnitine and pro-
pionyl-L-carnitine in human plasma by high-performance
liquid chromatography after pre-column derivatization with12 Oxidative Medicine and Cellular Longevity
1-aminoanthracene,” Journal of Chromatography B, vol. 686,
no. 2, pp. 129–139, 1996.
[35] H. E. Botker, H. H. Kimose, P. Helligso, and T. T. Nielsen,
“Analytical evaluation of high energy phosphate determina-
tion by high performance liquid chromatography in myocar-
dial tissue,” Journal of Molecular and Cellular Cardiology, vol.
26, no. 1, pp. 41–48, 1994.
[36] G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochem-
istry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959.
[37] S. Granados-Principal, J. L. Quiles, C. L. Ramirez-Tortosa, P.
Sanchez-Rovira, and M. Ramirez-Tortosa, “New advances in
molecular mechanisms and the prevention of adriamycin tox-
icity by antioxidant nutrients,” Food and Chemical Toxicology,
vol. 48, no. 6, pp. 1425–1438, 2010.
[38] K. B. Wallace, “Doxorubicin-induced cardiac mitochondri-
onopathy,” Pharmacology and Toxicology, vol. 93, no. 3, pp.
105–115, 2003.
[39] V.Lee,A.K.Randhawa,andP.K.Singal,“Adriamycin-induced
myocardial dysfunction in vitro is mediated by free radicals,”
American Journal of Physiology, vol. 261, no. 4, part 2, pp.
H989–H995, 1991.
[ 4 0 ]M .F .X u ,P .L .T a n g ,Z .M .Q i a n ,a n dM .A s h r a f ,“ E ﬀects by
doxorubicin on the myocardium are mediated by oxygen free
radicals,” Life Sciences, vol. 68, no. 8, pp. 889–901, 2001.
[ 4 1 ]S .Z h o u ,C .M .P a l m e i r a ,a n dK .B .W a l l a c e ,“ D o x o r u b i c i n -
induced persistent oxidative stress to cardiac myocytes,”
Toxicology Letters, vol. 121, no. 3, pp. 151–157, 2001.
[42] J. M. Berthiaume and K. B. Wallace, “Adriamycin-induced
oxidative mitochondrial cardiotoxicity,” Cell Biology and Toxi-
cology, vol. 23, no. 1, pp. 15–25, 2007.
[43] M. Tokarska-Schlattner, T. Wallimann, and U. Schlattner, “Al-
terations in myocardial energy metabolism induced by the
anti-cancer drug doxorubicin,” Comptes Rendus, vol. 329, no.
9, pp. 657–668, 2006.
[ 4 4 ]M .P r e u s ,A .S .B h a r g a v a ,A .E .K h a t e r ,a n dP .G u n z e l ,“ D i a g -
nostic value of serum creatine kinase and lactate dehydroge-
nase isoenzyme determinations for monitoring early cardiac
damage in rats,” Toxicology Letters, vol. 42, no. 2, pp. 225–233,
1988.
[45] M. A. Abd El-Aziz, A. I. Othman, M. Amer, and M. A. El-
Missiry, “Potential protective role of angiotensin-converting
enzyme inhibitors captopril and enalapril against adriamycin-
induced acute cardiac and hepatic toxicity in rats,” Journal of
Applied Toxicology, vol. 21, no. 6, pp. 469–473, 2001.
[46] M. E. B¨ uy¨ ukokuroˇ glu, S. Taysi, M. Buyukavci, and E. Bakan,
“Prevention of acute adriamycin cardiotoxicity by dantrolene
in rats,” Human and Experimental Toxicology, vol. 23, no. 5,
pp. 251–256, 2004.
[ 4 7 ]K .N a k a o ,W .M i n o b e ,R .R o d e n ,M .R .B r i s t o w ,a n dL .A .
Leinwand, “Myosin heavy chain gene expression in human
heart failure,” Journal of Clinical Investigation, vol. 100, no. 9,
pp. 2362–2370, 1997.
[48] B. D. Lowes, W. Minobe, W. T. Abraham et al., “Changes in
gene expression in the intact human heart: downregulation
of α-myosin heavy chain in hypertrophied, failing ventricular
myocardium,” Journal of Clinical Investigation, vol. 100, no. 9,
pp. 2315–2324, 1997.
[49] G. Cooper, “Basic determinants of myocardial hypertrophy: a
review of molecular mechanisms,” Annual Review of Medicine,
vol. 48, pp. 13–23, 1997.
[50] B. Swynghedauw, S. Besse, P. Assayag et al., “Molecular and
cellular biology of the senescent hypertrophied and failing
heart,” American Journal of Cardiology, vol. 76, no. 13, pp. 2D–
7D, 1995.
[51] C. Myers, “The roleof ironin doxorubicin-induced cardiomy-
opathy,” Seminars in Oncology, vol. 25, no. 4, supplement 10,
pp. 10–14, 1998.
[52] R.D.Olson,J.S.MacDonald,andC.J.VanBoxtel,“Regulatory
role of glutathione and soluble sulfhydryl groups in the toxic-
ity of adriamycin,” Journal of Pharmacology and Experimental
Therapeutics, vol. 215, no. 2, pp. 450–454, 1980.
[53] A. Meister, “Metabolism and functions of glutathione,” Trends
in Biochemical Sciences C, vol. 6, pp. 231–234, 1981.
[54] A. Meister and M. E. Anderson, “Glutathione,” Annual Review
of Biochemistry, vol. 52, pp. 711–760, 1983.
[55] A. Meister, “On the discovery of glutathione,” Trends in Bio-
chemical Sciences, vol. 13, no. 5, pp. 185–188, 1988.
[56] N. Iliskovic, T. Li, N. Khaper, V. Palace, and P. K. Singal,
“Modulation of adriamycin-induced changes in serum free
fatty acids, albumin and cardiac oxidative stress,” Molecular
andCellularBiochemistry,vol.188,no.1-2,pp.161–166,1998.
[57] M.Valko,D.Leibfritz,J.Moncol,M.T.Cronin,M.Mazur,and
J. Telser, “Free radicals and antioxidants in normal physio-
logical functions and human disease,” International Journal of
Biochemistry and Cell Biology, vol. 39, no. 1, pp. 44–84, 2007.
[58] A.M.Aleisa,S.S.Al-R ejaie,S.A.Bakheetetal.,“Eﬀectofmet-
formin on clastogenic and biochemical changes induced by
adriamycin in Swiss albino mice,” Mutation Research, vol. 634,
no. 1-2, pp. 93–100, 2007.
[ 5 9 ]S .Z h o u ,A .S t a r k o v ,M .K .F r o b e r g ,R .L .L e i n o ,a n dK .B .
Wallace, “Cumulative and irreversible cardiac mitochondrial
dysfunctioninducedbydoxorubicin,”CancerResearch,vol.61,
no. 2, pp. 771–777, 2001.
[60] P. Alin, U. H. Danielson, and B. Mannervik, “4-hydroxyalk-2-
enals are substrates for glutathione transferase,” FEBS Letters,
vol. 179, no. 2, pp. 267–270, 1985.
[61] P. Nioi and J. D. Hayes, “Contribution of NAD(P)H:quinone
oxidoreductase 1 to protection against carcinogenesis, and
regulation of its gene by the Nrf2 basic-region leucine zipper
and the arylhydrocarbon receptor basic helix-loop-helix tran-
scription factors,” Mutation Research, vol. 555, no. 1-2, pp.
149–171, 2004.
[62] P. Talalay and A. T. Dinkova-Kostova, “Role of nicotinamide
quinone oxidoreductase 1 (NQO1) in protection against tox-
icityofelectrophilesandreactiveoxygenintermediates,”Meth-
ods in Enzymology, vol. 382, pp. 355–364, 2004.
[63] K. Iida, K. Itoh, Y. Kumagai et al., “Nrf2 is essential for the
chemopreventive eﬃcacy of oltipraz against urinary bladder
carcinogenesis,” Cancer Research, vol. 64, no. 18, pp. 6424–
6431, 2004.
[64] L. A. Applegate, P. Luscher, and R. M. Tyrrell, “Induction of
heme oxygenase: a general response to oxidant stress in cul-
tured mammalian cells,” Cancer Research, vol. 51, no. 3, pp.
974–978, 1991.
[65] M. Rizzardini, M. Carelli, M. R. Cabello Porras, and L.
Cantoni,“Mechanismsofendotoxin-inducedhaemoxygenase
mRNAaccumulationinmouseliver:synergismbyglutathione
depletion and protection by N-acetylcysteine,” Biochemical
Journal, vol. 304, no. 2, pp. 477–483, 1994.
[66] M. C. Asensio-Lopez, A. Lax, D. A. Pascual-Figal, M. Valdes,
and J. Sanchez-Mas, “Metformin protects against doxorubi-
cin-induced cardiotoxicity: involvement of the adiponectin
cardiac system,” Free Radical Biology and Medicine, vol. 51, no.
10, pp. 1861–1871, 2011.
[67] L.M.Mela-RikerandR.D.Bukoski,“Regulationofmitochon-
drialactivityincardiaccells,”Annual Review of Physiology,vol.
47, pp. 645–663, 1985.Oxidative Medicine and Cellular Longevity 13
[68] S. Abdel-Aleem, M. M. El-Merzabani, M. Sayed-Ahmed, D. A.
Taylor,andJ.E.Lowe,“Acuteandchroniceﬀectsofadriamycin
onfattyacidoxidationinisolatedcardiacmyocytes,”Journalof
Molecular and Cellular Cardiology, vol. 29, no. 2, pp. 789–797,
1997.
[69] J. R. Neely and H. E. Morgan, “Relationship between carbo-
hydrate and lipid metabolism and the energy balance of heart
muscle.,” Annual Review of Physiology, vol. 36, pp. 413–459,
1974.
[ 7 0 ] R .B r e s s l e r ,R .G a y ,J .G .C o p e l a n d ,J .J .B a h l ,J .B e d o t t o ,a n dS .
Goldman, “Chronic inhibition of fatty acid oxidation: new
model of diastolic dysfunction,” Life Sciences, vol. 44, no. 25,
pp. 1897–1906, 1989.
[71] P.B.Corr,R.W.Gross,andB.E.Sobel,“Amphipathicmetabo-
lites and membrane dysfunction in ischemic myocardium,”
Circulation Research, vol. 55, no. 2, pp. 135–154, 1984.
[72] A. M. Katz and F. C. Messineo, “Lipid-membrane interactions
andthepathogenesisofischemicdamageinthemyocardium,”
Circulation Research, vol. 48, no. 1, pp. 1–16, 1981.
[ 7 3 ]G .P e l u s o ,R .N i c o l a i ,E .R e d a ,P .B e n a t t i ,A .B a r b a r i s i ,a n dM .
Calvani, “Cancer and anticancer therapy-induced modiﬁca-
tions on metabolism mediated by carnitine system,” Journal
of Cellular Physiology, vol. 182, no. 3, pp. 339–350, 2000.
[74] Y. Olowe and H. Schulz, “Regulation of thiolases from pig
heart. Control of fatty acid oxidation in heart,” European
Journal of Biochemistry, vol. 109, no. 2, pp. 425–429, 1980.
[75] W. W. Winder and D. G. Hardie, “AMP-activated protein
kinase, a metabolic master switch: possible roles in Type 2 dia-
betes,” American Journal of Physiology, vol. 277, no. 1, part 1,
pp. E1–E10, 1999.
[76] S. Goﬀart, J. C. von Kleist-Retzow, and R. J. Wiesner, “Reg-
ulation of mitochondrial proliferation in the heart: power-
plant failure contributes to cardiac failure in hypertrophy,”
Cardiovascular Research, vol. 64, no. 2, pp. 198–207, 2004.
[77] A. M. Katz, “The myocardium in congestive heart failure,”
American Journal of Cardiology, vol. 63, no. 2, pp. 12A–16A,
1989.